or
forgot password

An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)


Phase 3
18 Years
N/A
Not Enrolling
Both
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent, Carcinoma, Hepatocellular, Liver Diseases, Neoplasms by Histologic Type, Digestive System Neoplasms, Carcinoma, Liver Neoplasms, Neoplasms, Neoplasms by Site, Digestive System Diseases, Adenocarcinoma, Neoplasms, Glandular and Epithelial

Thank you

Trial Information

An Open-label, Randomized Phase 3 Study of the Efficacy and Tolerability of Linifanib (ABT-869) Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)


The IDMC recommended discontinuation of the study, and, the protocol was amended to end
study treatment.

Inclusion Criteria


Inclusion Criteria

- Histologic or cytologic diagnosis with unresectable or metastatic HCC

- Child Pugh Class A

- ECOG performance status 0-1

- Adequate hematologic, hepatic, and renal function

Exclusion Criteria

- Prior systemic (administered intravenously or orally rather than locoregionally)
treatment for HCC

- Prior local therapy (including liver-directed therapy) within 4 weeks from entry

- Untreated brain or meningeal metastases

- Current treatment on another clinical trial

- Pregnancy or breastfeeding

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Overall Survival

Outcome Time Frame:

From randomization until patient death; assessed monthly

Safety Issue:

No

Principal Investigator

Justin Ricker, MD

Investigator Role:

Study Director

Investigator Affiliation:

Abbott

Authority:

Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica

Study ID:

M10-963

NCT ID:

NCT01009593

Start Date:

January 2010

Completion Date:

July 2012

Related Keywords:

  • Hepatocellular Carcinoma Non-resectable
  • Hepatocellular Carcinoma Recurrent
  • Carcinoma, Hepatocellular
  • Liver Diseases
  • Neoplasms by Histologic Type
  • Digestive System Neoplasms
  • Carcinoma
  • Liver Neoplasms
  • Neoplasms
  • Neoplasms by Site
  • Digestive System Diseases
  • Adenocarcinoma
  • Neoplasms, Glandular and Epithelial
  • Molecular Mechanisms of Pharmacological Action
  • Antineoplastic Agents
  • Growth Substances
  • Physiological Effects of Drugs
  • Enzyme Inhibitors
  • Angiogenesis Inhibitors
  • Inhibitors, Angiogenesis
  • Protein Kinase Inhibitors
  • Pharmacologic Actions
  • Growth Inhibitors
  • Angiogenesis Modulating Agents
  • Sorafenib
  • Adenocarcinoma
  • Adenocarcinoma, Mucinous
  • Neoplasms
  • Carcinoma
  • Digestive System Diseases
  • Gastrointestinal Diseases
  • Digestive System Neoplasms
  • Gastrointestinal Neoplasms
  • Liver Diseases
  • Liver Neoplasms
  • Neoplasms by Histologic Type
  • Neoplasms by Site
  • Neoplasms, Glandular and Epithelial
  • Carcinoma, Hepatocellular

Name

Location
Site Reference ID/Investigator# 23247 Beverly Hills, California  90211-1850
Site Reference ID/Investigator# 23608 LaVerne, California  91750
Site Reference ID/Investigator# 23852 Orange, California  92868
Site Reference ID/Investigator# 40162 Orange, California  92868
Site Reference ID/Investigator# 23254 Newark, Delaware  19713
Site Reference ID/Investigator# 23253 Gainesville, Georgia  30505
Site Reference ID/Investigator# 24848 Honolulu, Hawaii  96819
Site Reference ID/Investigator# 23609 Honolulu, Hawaii  96813
Site Reference ID/Investigator# 23250 Louisville, Kentucky  40202
Site Reference ID/Investigator# 23257 St. Louis, Missouri  63104
Site Reference ID/Investigator# 23603 Las Vegas, Nevada  89135
Site Reference ID/Investigator# 23244 Durham, North Carolina  27710
Site Reference ID/Investigator# 23252 Portland, Oregon  97213